(Incorporated in the Cayman Islands) 

We are a clinical biopharmaceutical company in Malaysia with a focus on the development of pharmaceutical-grade botanical therapeutic treatments for obesity and metabolic syndrome.

Our lead product candidate, SKF7^® , is a patented standardized extract of Labisia pumila, a medicinal plant indigenous to Malaysia, that is being developed to treat abdominal obesity and metabolic syndrome. SKF7^® has been studied in Phase I and Phase II clinical trials in Malaysia, Indonesia, and India.

SKF7^® received New Dietary Ingredient (“NDI”) notification acceptance from the FDA in 2020 (for 300 mg) and 2022 (for 750 mg), permitting its lawful marketing as a dietary supplement in the United States at the notified doses. 

In 2023, SKF7^® received Novel Food authorization from the European Food Safety Authority (“EFSA”) for use in the general adult population up to 350 mg/day, except pregnant and lactating women. While this EFSA opinion supports the safety of SKF7^® for adult use, there is no guarantee that the FDA will agree or reach a similar conclusion. Medikra has not yet submitted an Investigational New Drug (“IND”) application to the FDA or a Clinical Trial Application (“CTA”) to any European regulatory authority for SKF7^®. 

Note: Net loss and revenue are in U.S. dollars for the 12 months that ended June 30, 2025. 

(Note: Medikra Inc. is offering 3.64 million shares at a price range of $5.00 to $6.00 to raise $20.02 million, if priced at the $5.50 mid-point of its range, according to its F-1 filing dated Jan. 20, 2026.)